INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED

Innovative Pharmaceutical Biotech Limited

399 BMG4783W1073

Industrial Machinery & Equipment

Market Closed - Hong Kong S.E. Other stock markets 04:08:27 2024-07-12 am EDT			5-day change	1st Jan Change
0.229 ^HKD	+0.44%		+1.33%	+4.57%

Jun. 28	Innovative Pharmaceutical Biotech Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI
Jun. 26	Innovative Pharmaceutical Renews THU Agreement, Revises Product's Commercialization Timeline	MT

Innovative Pharmaceutical Biotech Limited announced that it has received HKD 55.5 million in funding

June 20, 2024

On June 21, 2024, Innovative Pharmaceutical Biotech Limited closed the transaction.

Latest news about Innovative Pharmaceutical Biotech Limited

Innovative Pharmaceutical Biotech Limited Reports Earnings Results for the Full Year Ended March 31, 2024	Jun. 28	CI
Innovative Pharmaceutical Renews THU Agreement, Revises Product's Commercialization Timeline	Jun. 26	MT
Innovative Pharmaceutical Biotech Limited Provides Update on the Status of the Commercialization of the Oral Insulin Product (The "Product") and the Latest Business Development of the Group	Jun. 25	CI
Innovative Pharmaceutical Biotech Limited announced that it has received HKD 55.5 million in funding	Jun. 20	CI
Innovative Pharma Extends Long Stop Date for Convertible Bond Issuance	May. 31	MT
Innovative Pharmaceutical Biotech Returns to Fiscal H1 Attributable Profit	Nov. 30	MT
Innovative Pharmaceutical Biotech Limited Reports Earnings Results for the Half Year Ended September 30, 2023	Nov. 29	CI
Innovative Pharmaceutical Biotech to Return to Profit in Fiscal H1	Nov. 28	MT
Innovative Pharmaceutical Biotech Limited Provides Unaudited Earnings Guidance for the Six Months Ended 30 September 2023	Nov. 27	CI
Innovative Pharmaceutical Biotech Limited Announces Change of Address of Principal Place of Business in Hong Kong	Nov. 07	CI
Innovative Pharmaceutical Eyes Majority Stake in US Neurotechnology Firm	23-09-05	MT
Innovative Pharmaceutical Biotech Limited entered into a memorandum of understanding to acquire a majority interest in Niraxx Light Therapeutics, Inc.	23-09-03	CI
Innovative Pharmaceutical Plans HK$55.5 Million Bond Issue	23-07-28	MT
Innovative Pharmaceutical to Raise HK$58 Million From Deal with US Firm Genuine Marketing	23-07-27	MT
Innovative Pharmaceutical Biotech Limited announced that it expects to receive HKD 55.5 million in funding	23-07-26	CI
Innovative Pharmaceutical Biotech Limited Appoints Cheng Tak Yiu as an Executive Director	23-07-04	CI
Innovative Pharmaceutical Biotech Incurs Loss in Fiscal Year 2023	23-06-29	MT
Innovative Pharmaceutical Biotech Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-06-29	CI
Innovative Pharmaceutical Biotech Mulls Over Capital Injection in Technical Services Company	23-01-20	MT
Innovative Pharmaceutical Biotech Limited Reports Earnings Results for the Half Year Ended September 30, 2022	22-11-29	CI
Innovative Pharmaceutical Biotech Forecasts Swing to Loss in April-September Period	22-11-24	MT
Innovative Pharmaceutical Biotech Limited Provides Group Earnings Guidance for the Six Months Ending 30 September 2022	22-11-24	CI
Innovative Pharmaceutical Biotech Limited Auditor Raises 'Going Concern' Doubt	22-07-28	CI
Innovative Pharmaceutical Biotech Limited Announces Delay in Publication of Audited Annual Results for the Year Ended 31 March 2022	22-06-29	CI
Innovative Pharmaceutical Biotech Limited Reports Earnings Results for the Full Year Ended March 31, 2022	22-06-29	CI

Chart Innovative Pharmaceutical Biotech Limited

Duration

Period

Chart Innovative Pharmaceutical Biotech Limited

More charts

Innovative Pharmaceutical Biotech Limited is a Hong Kong-based investment holding company principally engaged in pharmaceuticals and biotechnology businesses. The Company operates through five segments. Genetic Testing Services segment is engaged in the provision of genetic testing services in the Peopleâs Republic of China (PRC) and Hong Kong. Bio-Industrial Products segment is engaged in the distribution of bio-industrial products in the PRC. Beauty Equipment and Products segment is engaged in the trading of beauty equipment and products in Hong Kong. Securities Investment segment is engaged in securities investment in Hong Kong and outside Hong Kong. Research and Development segment is engaged in the research, development and commercialization of the oral insulin products.

Sector

Industrial Machinery & Equipment

Calendar

2024-11-26 - Q2 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Industrial Machinery & Equipment Wholesale

	1st Jan change	Capi.
INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED	+4.57%	50.32M
W.W. GRAINGER, INC.	+10.83%	44.36B
APPLIED INDUSTRIAL TECHNOLOGIES, INC.	+12.08%	7.38B
DIPLOMA PLC	+20.27%	7.37B
MSC INDUSTRIAL DIRECT CO., INC.	-21.66%	4.38B
DNOW INC.	+19.61%	1.44B
DISTRIBUTION SOLUTIONS GROUP, INC.	-2.47%	1.43B
BUFAB AB	+12.37%	1.43B
MRC GLOBAL INC.	+23.71%	1.13B
TRUSCO NAKAYAMA CORPORATION	+1.72%	1B

Industrial Machinery & Equipment Wholesale